MenACWY: Clinical Trials

8 trials of MenACWY, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed. 8 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 28Completed 8
Phase 12Completed 2

Follow MenACWY: new trials by email Literature Review of MenACWY trials Research Report on MenACWY

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants.
Shigella4V2, MenACWY - Shigellosis
Phase 2CompletedLimmaTech Biologics AG1102025-04-072026-08-07
A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants
iNTS-GMMA Dose C, iNTS-GMMA Dose B, iNTS-GMMA Dose A - Salmonella Infections
Phase 2CompletedGlaxoSmithKline1802024-01-152026-09-21
A Study of a Candidate COVID-19 Vaccine (COV001)
ChAdOx1 nCoV-19, MenACWY, ChAdOx1 nCoV-19 full boost - Coronavirus
Phase 1 / Phase 2CompletedUniversity of Oxford10772020-04-232025-09-03
A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants
Shigella 4V, MenACWY, Rabies - Shigellosis
Phase 1 / Phase 2CompletedLimmaTech Biologics AG5972019-09-022026-06-23
A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants
Ad26.ZEBOV, MVA-BN-Filo, MenACWY - Ebola Virus Disease
Phase 2CompletedJanssen Vaccines & Prevention B.V.1082019-08-192025-05-25
A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age
MenACWY liquid, MenACWY - Meningitis, Meningococcal
Phase 2CompletedGlaxoSmithKline17072018-08-302021-02-17
Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years
MenABCWY vaccine, rMenB+OMV NZ (Bexsero) vaccine, MenACWY (Menveo) vaccine - Meningitis, Meningococcal
Phase 2CompletedGlaxoSmithKline5202018-07-092020-02-12
Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents
MenABCWY, Placebo, MenACWY - Meningococcal Disease
Phase 2CompletedNovartis Vaccines3052014-05-012018-09-12

Conditions studied

Dysentery, Bacillary (2)  ·  Meningitis (2)  ·  Meningitis, Meningococcal (2)  ·  Meningococcal Infections (2)  ·  COVID-19 (1)  ·  Coronavirus Infections (1)  ·  Hemorrhagic Fever, Ebola (1)  ·  Salmonella Infections (1)

Sponsors

GlaxoSmithKline (3)  ·  LimmaTech Biologics AG (2)  ·  Janssen Vaccines & Prevention B.V. (1)  ·  Novartis Vaccines (1)  ·  University of Oxford (1)

Countries

Kenya (2)  ·  Brazil (1)  ·  Czechia (1)  ·  Estonia (1)  ·  Finland (1)  ·  France (1)  ·  Ghana (1)  ·  Guinea (1)  ·  Mexico (1)  ·  Russia (1)  ·  Sierra Leone (1)  ·  South Africa (1)  ·  Spain (1)  ·  Turkey (Türkiye) (1)  ·  United Kingdom (1)

Top investigators

Andrew Pollard, Prof (1)  ·  Josphat Kosgei, MD (1)  ·  Mainga Hamaluba, MD (1)  ·  Richard Omore, PhD (1)

Results publications

PMID 30061029, PMID 32702298, PMID 33306989, PMID 33335322, PMID 33617777, PMID 34480858, PMID 34787449, PMID 35257644, PMID 36369456, PMID 37138460, PMID 37858585

NIH funding

2017 (2)